Publications by authors named "Wayel Zanjir"
Article Synopsis
- IgG4-related disease (IgG4-RD) is a recently identified immune disorder that causes inflammatory masses affecting various organs, making it hard to diagnose and potentially underrecognized.
- Key renal complications include tubulointerstitial nephritis, but other issues like membranous glomerulonephritis, renal masses, and retroperitoneal fibrosis have also been noted.
- The review aims to summarize the history and symptoms of IgG4-RD while focusing on its renal effects, including important aspects like histology, imaging, and treatment to increase awareness among healthcare professionals.
Background: Hyperkalemia is common among patients on maintenance hemodialysis (HD) and is associated with mortality. We hypothesized that clinical characteristics available at time of paramedic assessment before emergency department (ED) ambulance transport (ambulance-ED) would associate with severe hyperkalemia (K≥6 mmol/L). Rapid identification of patients who are at risk for hyperkalemia and thereby hyperkalemia-associated complications may allow paramedics to intervene in a timely fashion, including directing emergency transport to dialysis-capable facilities.
View Article and Find Full Text PDFTenofovir disoproxil fumarate (TDF) effectively suppresses viral replication in chronic hepatitis B (CHB), but occasionally leads to renal impairment. We evaluated the prevalence of viral and biochemical breakthrough and renal function kinetics in renally impaired patients with CHB on reduced and on full-dose TDF. This clinic-based longitudinal cohort study included patients receiving full and reduced dose TDF (due to eGFR [Cockcroft-Gault] <60 mL/min/1.
View Article and Find Full Text PDFBackground: The causal link of sustained virologic response (SVR) with outcome has been challenged. With improved SVR rates with direct-acting antivirals (DAAs), the benefit of SVR would be expected to diminish if the association with outcome is not causal.
Methods: Data were collected for patients starting treatment with interferon (IFN) or DAAs between June 2006 and December 2016.
Background And Aims: Chronic hepatitis B (CHB) and nonalcoholic fatty liver disease are increasingly observed together in clinical practice, and development of nonalcoholic steatohepatitis (NASH) represents another leading cause of liver-related morbidity and mortality. Our aims were to determine whether biopsy-proven NASH impacts clinical outcomes in CHB patients and assess prognostic risk factors.
Approach And Results: CHB patients attending two tertiary centers in North America and Europe over 13 years with available clinical and biopsy data were included.
Background & Aims: The use of complementary and alternative medicine (CAM) in patients with chronic hepatitis B (CHB) can interact with antiviral treatment or influence health-seeking behaviour. We aimed to study the use of individual CAM modalities in CHB and explore determinants of use, particularly migration-related, socio-economic and clinical factors.
Methods: A total of 436 CHB outpatients who attended the Toronto Centre for Liver Disease in 2015-2016 were included in this cross-sectional study.